Document is current
Any future updates will be listed below
-
Authors
Schultz, Olaf https://orcid.org/0009-0007-4310-8854
Fiehn, Christoph https://orcid.org/0000-0001-9665-1526
Kneitz, Christian https://orcid.org/0000-0002-6859-9043
Picker, Nils https://orcid.org/0000-0001-5328-4332
Kromer, Daniel https://orcid.org/0000-0002-0770-6247
Zignani, Monia https://orcid.org/0009-0006-9210-8087
De Leonardis, Francesco https://orcid.org/0009-0003-3247-4462
Orzechowski, Hans-Dieter https://orcid.org/0000-0001-7374-6899
Gurrath, Margot https://orcid.org/0009-0005-2334-7618
Krüger, Klaus
- License Information
-
More Information
Article History
Accepted: 21 March 2024
First Online: 30 April 2024
Declarations
:
: O. Schultz reports speaker fees from Abbott, BMS, Galapagos, MSD, Novartis and Pfizer. C. Fiehn reports consultancy fees from Boehringer Ingelheim, Eli Lilly and Galapagos; and speaker fees from AbbVie, AstraZeneca, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Medac, MSD, Novartis, Pfizer, Sanofi and UCB. C. Kneitz reports consultancy fees from Fresenius, Galapagos, Lilly, and Mylan; and speaker fees from AbbVie, Berlin-Chemie, Boehringer-Ingelheim, Celgene, Galapagos, Gilead, GSK, Janssen, Lilly, MSD, Novartis, Pfizer, Sanofi, and UCB. M. Zignani is an employee of, and shareholders in, Galapagos. F. De Leonardis is an employee of, and shareholders in, Galapagos. H.-D. Orzechowski is a former employee of Galapagos Biopharma GmbH Germany and is a shareholder in Gilead Sciences. M. Gurrath is an employee of Galapagos Biopharma GmbH Germany and a shareholder in Gilead Sciences. K. Krüger reports consultancy fees and speaker fees from Galapagos and Gilead. N. Picker and D. Kromer declare that they have no competing interests.
: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.
